EFG Asset Management Americas Corp. Sells 87 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

EFG Asset Management Americas Corp. trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,102 shares of the medical equipment provider’s stock after selling 87 shares during the quarter. EFG Asset Management Americas Corp.’s holdings in Intuitive Surgical were worth $372,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Portside Wealth Group LLC increased its position in shares of Intuitive Surgical by 8.2% during the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after acquiring an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after acquiring an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC purchased a new stake in shares of Intuitive Surgical during the fourth quarter valued at approximately $230,000. Blair William & Co. IL increased its position in shares of Intuitive Surgical by 3.1% during the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after acquiring an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Intuitive Surgical by 21.2% during the third quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after acquiring an additional 129,194 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In other news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP Myriam Curet sold 4,318 shares of the business’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the transaction, the executive vice president now owns 189 shares in the company, valued at approximately $69,958.35. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 248,418 shares of company stock worth $95,927,097. Company insiders own 0.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ISRG. Wells Fargo & Company raised their target price on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. Barclays lifted their price target on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Raymond James lifted their price target on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Stifel Nicolaus lifted their price target on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, Robert W. Baird dropped their price objective on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Stock Up 0.7 %

Shares of ISRG stock opened at $369.00 on Monday. The business has a 50-day moving average price of $386.84 and a two-hundred day moving average price of $343.86. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The firm has a market cap of $130.79 billion, a P/E ratio of 66.13, a price-to-earnings-growth ratio of 5.69 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 earnings per share. As a group, research analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.